Satoshi Miyamoto

Years Active: 2022-2022
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Satoshi Miyamoto, Hiddo J Lambers Heerspink, Dick de Zeeuw, Masao Toyoda, Daisuke Suzuki, Takashi Hatanaka, Tohru Nakamura, Shinji Kamei, Satoshi Murao, Kazuyuki Hida, Shinichiro Ando, Hiroaki Akai, Yasushi Takahashi, Daisuke Koya, Munehiro Kitada, Hisashi Sugano, Tomokazu Nunoue, Akihiko Nakamura, Motofumi Sasaki, Tatsuaki Nakatou, Kei Fujimoto, Daiji Kawanami, Takashi Wada, Nobuyuki Miyatake, Michihiro Yoshida, Kenichi Shikata, null null
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study. Diabetes, obesity & metabolism 24 (8) (2022)
Kaori Oda, Satoshi Miyamoto, Ryo Kodera, Jun Wada, Kenichi Shikata
Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice. Journal of diabetes investigation (2022)

Satoshi Miyamoto.css-eqlu8i{font-size:small;padding-left:4px;}